Last news
Everest Medicines Announces NEFECON®, the World's First Approved Treatment for IgA Nephropathy, is Included in China's National Reimbursement Drug List

Everest Medicines Announces NEFECON®, the World's First Approved Treatment for IgA Nephropathy, is Included in China's National Reimbursement Drug List

SHANGHAI, Nov. 28, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today...

Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country

Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country

SHANGHAI and HONG KONG, Nov. 28, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing...

ASSEMBLY ELEVATES VIVIAN MOK TO SVP & MANAGING DIRECTOR FOR NORTH ASIA

ASSEMBLY ELEVATES VIVIAN MOK TO SVP & MANAGING DIRECTOR FOR NORTH ASIA

Mok will be pivotal in solidifying Assembly's proposition and accelerating the agency's growth in North Asia SEOUL, South Korea, Nov. 28, 2024 /PRNewswire/ -- Assembly, a leading global omnichannel media agency, announced today the promotion of...

Innovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China's National Reimbursement Drug List

Innovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China's National Reimbursement Drug List

SAN FRANCISCO and SUZHOU, China, Nov. 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of...

Team T5 Applauded by Frost & Sullivan for Deeply and Effectively Monitoring Regional Adversaries and Incidents

Team T5 Applauded by Frost & Sullivan for Deeply and Effectively Monitoring Regional Adversaries and Incidents

With offices in Taiwan and Japan, TeamT5 provides in-depth localized threat intelligence, especially for organizations targeted by Chinese adversaries. SAN ANTONIO, Nov. 28, 2024 /PRNewswire/ -- Frost & Sullivan recently assessed the threat...

Akeso Announced the Inclusion in China's National Reimbursement Drug List of Cadonilimab and Ivonescimab

Akeso Announced the Inclusion in China's National Reimbursement Drug List of Cadonilimab and Ivonescimab

HONG KONG, Nov. 28, 2024 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce that two of its independently developed, globally pioneering bispecific antibody drugs—cadonilimab Injection (PD-1/CTLA-4 bispecific...

Hangzhou Hosts Second Liangzhu Forum with Global Cultural Leaders

Hangzhou Hosts Second Liangzhu Forum with Global Cultural Leaders

HANGZHOU, China, Nov. 28, 2024 /PRNewswire/ -- The Second Liangzhu Forum, an assembly of global cultural experts, commenced in Hangzhou, Zhejiang Province on November 25, 2024. This year's forum, under the theme "Exchange and Mutual Enlightenment,...

Global Times: Dialogue across Yangtze, Rhine, Danube bridges mutual learning between China and Europe

Global Times: Dialogue across Yangtze, Rhine, Danube bridges mutual learning between China and Europe

BEIJING, Nov. 28, 2024 /PRNewswire/ -- When Chinese scholar Li Xiuzhen first saw the Rhine River while studying in the Netherlands in 1996, she was deeply impressed by the river's crystal-clear waters, similar to that of China's Yangtze River....

menu
menu